DALY II Japan/MB-CART2019.1 for DLBCL

A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies

NCT05836896 ·Status: RECRUITING ·Phase: PHASE1

The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma

NCT05673447 ·Status: UNKNOWN ·Phase: EARLY_PHASE1

Safety, Efficacy and Pharmacokinetics of XKDCT023 in DLBCL

NCT05269914 ·Status: UNKNOWN ·Phase: NA

ThisCART19A for B-NHL Relapsed After Auto-CAR T

NCT05691153 ·Status: RECRUITING ·Phase: PHASE1

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma

NCT04718883 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

L218CAR19 in Patients With Relapsed/Refractory B-cell Lymphoma

NCT06478381 ·Status: RECRUITING ·Phase: PHASE1

Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

NCT03355859 ·Status: UNKNOWN ·Phase: PHASE1

A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies

NCT06703892 ·Status: RECRUITING ·Phase: PHASE1

Dual Target CAR-T Cells in B-cell Lymphoma

NCT04723914 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia

NCT06081478 ·Status: RECRUITING ·Phase: PHASE2

Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT

NCT03455972 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19

NCT01864889 ·Status: UNKNOWN ·Phase: NA

Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma

NCT03207178 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Research Development（RD）13-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7（CD7）+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML)

NCT05907603 ·Status: COMPLETED ·Phase: EARLY_PHASE1

Sequential Low-dose Decitabine With PD-1/CD28 CD19 CAR-T in Relapsed or Refractory B-cell Lymphoma

NCT04850560 ·Status: UNKNOWN ·Phase: PHASE1

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma

NCT04089215 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Exploratory Clinical Study of CD19-targeted CAR-T and CAR-DC in the Treatment of Relapsed and Refractory B-cell Lymphoma

NCT05585996 ·Status: RECRUITING ·Phase: PHASE1

Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma

NCT05535673 ·Status: UNKNOWN ·Phase: PHASE1

Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma

NCT06830031 ·Status: RECRUITING ·Phase: PHASE1

CART-19 Cells For MRD Positive CD19+ ALL

NCT03027739 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma

NCT04609241 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1

A Phase I Dose Finding Study of MB-CART2219.1

NCT07108868 ·Status: RECRUITING ·Phase: PHASE1

Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma

NCT03468153 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Clinical Study of Multi-targeted CAR-T Therapy in Patients With Relapsed/Refractory B-Cell Lymphoma

NCT07093086 ·Status: WITHDRAWN ·Phase: PHASE1

Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma

NCT02728882 ·Status: UNKNOWN ·Phase: NA